John Park

机构：California Baptist University, General Marble (Greece), Macquarie University · ORCID：0000-0001-9290-8179

发表论文 454 篇 · 总被引 14384 次 · h-index 52

代表论文

• D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial (2025 · Nature Medicine · 被引 21)
• JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trials. (2025 · Journal of Clinical Oncology · 被引 9)
• Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma (2025 · European Journal of Cancer · 被引 8)
• A pooled analysis of JSKN003, a biparatopic anti-HER2 antibody conjugate (ADC), in patients with advanced HER2-overexpressing (IHC 3+) gastrointestinal tumors. (2025 · Journal of Clinical Oncology · 被引 5)
• Abstract CT266: D3S-001, a next generation GDP-bound KRAS G12C inhibitor, as monotherapy in KRAS G12C inhibitor resistant non-small cell lung cancer (2025 · Cancer Research · 被引 1)
• Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance (2026 · Clinical Cancer Research)